*We are also developing Envelta™ for a second indication, PES200, which utilizes the same delivery mechanism and active as Envelta™. PES200 enables the delivery of a metabolically labile peptide drug (enkephalin) into the brain for post-traumatic stress disorder. PES200 development plan is pending a grant approval.
Further, we recently entered into a Collaboration and License Agreement with Nanomerics Ltd. for the exclusive North American license to develop and commercialize a High-Density Molecular Masking Spray (“MMS019”) as an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans. We plan to develop MMS019 primarily through grants.